Novo Nordisk A/S NVO New York Stock Exchange

Novo Nordisk A/S (NVO) has shown strong revenue growth over the past 3 years, expanding from $177.0B to $297.2B (average +19.5%/yr). Net income reached $98.5B, reflecting exceptional earnings expansion at +23%/yr on average. The net profit margin is 33.1%, which is exceptional. The company has maintained profitability in all 4 of the past 4 years, demonstrating a consistent earnings track record. The gross margin is 80.3% (high), with a -3.6pp trend over the period. With a $175B market cap and MOAT composite score of 85/100, the company has a strong competitive position.

Criteria proven by this page:

• GROWTH (90/100, Pass) — proving strong growth momentum
• PAST (100/100, Pass) — proving consistent earnings. Looking at the full 41-year history, the company was profitable in 41 of 41 years — a perfect long-term track record
• INCOME (100/100, Pass) — proves strong profitability and pricing power
• MOAT (85/100, Pass) — strong gross margins and market scale prove a durable competitive advantage

Overall SharesGrow Score: 81/100 with 5/7 criteria passed.